MARX Biotech Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	618.23	289.93	110.64	-
Revenue Growth (YoY)	113.24%	162.04%	-	-
Cost of Revenue	188.16	75.33	26.43	-
Gross Profit	430.07	214.59	84.21	-
Selling, General & Admin	481.47	228.33	82.32	0.83
Research & Development	25.99	0.6	-	-
Operating Expenses	515.07	231.48	83.31	0.83
Operating Income	-85	-16.89	0.9	-0.83
Interest Expense	-2.21	-0.37	-0.11	-
Interest & Investment Income	0.85	0.53	0.04	-
Earnings From Equity Investments	-	-	-	4.97
Other Non Operating Income (Expenses)	-11.07	1.24	4.09	0.15
Pretax Income	-97.43	-15.49	4.91	4.29
Income Tax Expense	-0.61	-2.57	2.08	-0.14
Net Income	-96.83	-12.92	2.83	4.43
Net Income to Common	-96.83	-12.92	2.83	4.43
Net Income Growth	-	-	-36.04%	-
Shares Outstanding (Basic)	498	425	346	32
Shares Outstanding (Diluted)	498	425	348	32
Shares Change (YoY)	17.36%	21.90%	982.64%	-
EPS (Basic)	-0.19	-0.03	0.01	0.14
EPS (Diluted)	-0.19	-0.03	0.01	0.14
EPS Growth	-	-	-94.05%	-
Free Cash Flow	-314.87	-15.18	10.74	0.31
Free Cash Flow Per Share	-0.63	-0.04	0.03	0.01
Dividend Per Share	-	-	0.080	-
Gross Margin	69.56%	74.02%	76.11%	-
Operating Margin	-13.75%	-5.83%	0.81%	-
Profit Margin	-15.66%	-4.46%	2.56%	-
Free Cash Flow Margin	-50.93%	-5.24%	9.71%	-
EBITDA	-67.36	-14.23	1.14	-
EBITDA Margin	-10.90%	-4.91%	1.03%	-
D&A For EBITDA	17.64	2.66	0.24	-
EBIT	-85	-16.89	0.9	-0.83
EBIT Margin	-13.75%	-5.83%	0.81%	-
Effective Tax Rate	-	-	42.30%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.